[Endometrial carcinomas in 2021: What to say and what to do?]

Abstract

The treatment of endometrial carcinomas relies on histopathological data such as tumor type, grade, stage, and lymphovascular invasion. We herein present the recent advances in the pathological appreciation of these criteria, relying in the last 2020 WHO classification of female genital tumours. Furthermore, molecular typing of endometrial carcinoma has become a rule with strong prognostic and therapeutic implications. The TP53-mutated/serous-like and hypermutated/dMMR groups can be easily identified by the pathologist using immunohistochemistry. The ultramutated/POLE-mutated group identification requires sequencing technologies. We herein explain how easily incorporate this novel histomolecular classification, now included in scholarly society recommendations, in the pathologist routine.

Keywords: Carcinome endométrial; Carcinome endométrioïde; Carcinome séreux; Endometrial carcinoma; Endometrioid carcinoma; Instabilité microsatellitaire; Microsatellite instability; Mutation POLE; Mutation TP53; POLE mutation; Serous carcinoma; TP53 mutation.